Journal profile · IMMUNOLOGYINFECTIOUS DISEASES&-INFECTIOUS DISEASES
Lancet HIV
ISSN 2352-3018 · Elsevier Ltd · ENGLAND
Lancet HIV: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 14.2; hybrid open access; APC about USD 7,280; median 77 days to acceptance (67 articles, last 24 months); 189 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Lancet HIV is published by Elsevier Ltd and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are HIV/AIDS Research and Interventions, HIV, Drug Use, Sexual Risk and HIV/AIDS drug development and treatment, together about 52.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Delivering a holistic view of the pandemic, The Lancet HIV publishes original research, comment, and correspondence that unifies clinical, epidemiological, and operational disciplines across a single vision of health for those living with HIV. The journal is the global leader for essential original research in the field, covering innovative treatments and the biological research underpinning such developments, novel methods of service delivery, and new ways of confronting HIV/AIDS worldwide.
From the journal's Aims & Scope
Research area (LetPub): IMMUNOLOGYINFECTIOUS DISEASES&-INFECTIOUS DISEASES
Main research topics OpenAlex counts of recent articles; shares are approximate
- HIV/AIDS Research and InterventionsMedicine29%
- HIV, Drug Use, Sexual RiskMedicine11.8%
- HIV/AIDS drug development and treatmentMedicine11.5%
- HIV Research and TreatmentImmunology and Microbiology11.2%
- HIV-related health complications and treatmentsMedicine7.8%
- Adolescent Sexual and Reproductive HealthHealth Professions5.9%
- HIV/AIDS Impact and ResponsesEconomics, Econometrics and Finance4.2%
- Sex work and related issuesSocial Sciences3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Immunology | Zone 1 |
| Minor | Infectious Diseases | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Immunology | Zone 1 |
| Minor | Infectious Diseases | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Immunology | Zone 1 |
| Minor | Infectious Diseases | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 14.2LetPub ·
- Impact factor (publisher)
- 14.6Publisher website ·
- CiteScore 2026-06
- 18.9LetPub ·
- CiteScore (publisher)
- 18.9Publisher website ·
- SJR 2026-06
- 4.76LetPub ·
- SNIP 2026-06
- 4.07LetPub ·
- h-index
- 34LetPub ·
- h-index
- 121OpenAlex ·
- i10-index
- 792OpenAlex ·
- 2-year mean citedness
- 5.79OpenAlex ·
- Self-citation rate
- 4.8%LetPub ·
- Share of gold OA articles
- 20.79%LetPub ·
Volume
- Articles per year
- 73LetPub ·
Articles by year OpenAlex count · 2,068 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 121 | 32 | 87 |
| 2025 | 189 | 65 | 919 |
| 2024 | 173 | 74 | 1,791 |
| 2023 | 175 | 92 | 3,216 |
| 2022 | 201 | 106 | 4,105 |
| 2021 | 149 | 79 | 5,290 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
77 daysMedian, submission to acceptance · P25–P75 26 days – 136 days
- Acceptance to online
- median 65 days (59 articles)
- Submission to online
- median 163 days
- Sample
- 67 articles with submission and acceptance dates (366 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 46 daysPublisher website ·
- Submission to acceptance
- 74 daysPublisher website ·
- Acceptance to publication
- 71 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 7,280 / EUR 6,810 / GBP 5,830 / JPY 902,940 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Elsevier Ltd
- Country or region
- ENGLAND
- Language
- English
- ISSN
- 2352-3018
- Print ISSN
- 2405-4704
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Lancet HIV
What CAS zone is Lancet HIV in?
In the 2025 upgraded edition of the CAS Journal Ranking, Lancet HIV is in Zone 1 of Medicine, and in Zone 1 of the minor category Immunology / Infectious Diseases; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Lancet HIV?
The latest impact factor listed by LetPub is 14.2; CiteScore 18.9, h-index 121.
How long does peer review take at Lancet HIV?
Based on the dates recorded on 67 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 77 days (interquartile range 26–136 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Lancet HIV?
According to LetPub and DOAJ records, Lancet HIV is indexed in SCIE and Scopus.
Is Lancet HIV open access, and what is the APC?
Lancet HIV is a hybrid journal. For open-access publication: APC about USD 7,280.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .